Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated-dose safety and pharmacokinetics of oral A4250 in healthy Japanese adults
jRCT2071220050Phase 1Completed
- Sponsor
- Jadeite Medicines
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in progressive familial intrahepatic cholestasis (PFIC) comparing A4250 3 mg with Placebo (2 arms). Primary endpoints: Safety endpoints, Pharmacokinetic endpoints and 1 more. Started Sep 2022; status: completed.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on jRCT2071220050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220050.